CA1148165A - Esters de l'acide arylepropionique ayant une activite anti-inflammatoire, procede de preparation, et composes pharmaceutiques les contenant - Google Patents
Esters de l'acide arylepropionique ayant une activite anti-inflammatoire, procede de preparation, et composes pharmaceutiques les contenantInfo
- Publication number
- CA1148165A CA1148165A CA000372274A CA372274A CA1148165A CA 1148165 A CA1148165 A CA 1148165A CA 000372274 A CA000372274 A CA 000372274A CA 372274 A CA372274 A CA 372274A CA 1148165 A CA1148165 A CA 1148165A
- Authority
- CA
- Canada
- Prior art keywords
- propionic acid
- phenyl
- tetraethylene glycol
- aryl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 title claims abstract description 19
- 239000002253 acid Substances 0.000 title claims abstract description 12
- 150000002148 esters Chemical class 0.000 title claims abstract description 10
- 150000007513 acids Chemical class 0.000 title claims abstract description 8
- 238000002360 preparation method Methods 0.000 title claims abstract description 5
- 230000003110 anti-inflammatory effect Effects 0.000 title abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 3
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 13
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 32
- 150000001875 compounds Chemical class 0.000 claims description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- -1 1-oxo-2-isoindolinyl residue Chemical group 0.000 claims description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 4
- CMWTZPSULFXXJA-UHFFFAOYSA-N 2-(6-methoxy-2-naphthalenyl)propanoic acid Chemical compound C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 3
- 150000008064 anhydrides Chemical group 0.000 claims description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 9
- 239000000126 substance Substances 0.000 claims 7
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims 2
- RJMIEHBSYVWVIN-UHFFFAOYSA-N indoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-UHFFFAOYSA-N 0.000 claims 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 230000002496 gastric effect Effects 0.000 abstract description 5
- 230000002035 prolonged effect Effects 0.000 abstract description 4
- 231100000053 low toxicity Toxicity 0.000 abstract description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 229960001680 ibuprofen Drugs 0.000 description 25
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 235000010418 carrageenan Nutrition 0.000 description 7
- 229920001525 carrageenan Polymers 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000007912 intraperitoneal administration Methods 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
- 229960004373 acetylcholine Drugs 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N anhydrous n-heptane Natural products CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 241000978776 Senegalia senegal Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- TUZRJGVLAFMQEK-UHFFFAOYSA-N 2-[4-(2-methylpropyl)phenyl]propanoic acid Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1.CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 TUZRJGVLAFMQEK-UHFFFAOYSA-N 0.000 description 1
- RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229910052925 anhydrite Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 231100000319 bleeding Toxicity 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000000544 hyperemic effect Effects 0.000 description 1
- 229940082151 ibuprofen 100 mg Drugs 0.000 description 1
- JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001562 ulcerogenic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000372274A CA1148165A (fr) | 1981-03-04 | 1981-03-04 | Esters de l'acide arylepropionique ayant une activite anti-inflammatoire, procede de preparation, et composes pharmaceutiques les contenant |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000372274A CA1148165A (fr) | 1981-03-04 | 1981-03-04 | Esters de l'acide arylepropionique ayant une activite anti-inflammatoire, procede de preparation, et composes pharmaceutiques les contenant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1148165A true CA1148165A (fr) | 1983-06-14 |
Family
ID=4119375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000372274A Expired CA1148165A (fr) | 1981-03-04 | 1981-03-04 | Esters de l'acide arylepropionique ayant une activite anti-inflammatoire, procede de preparation, et composes pharmaceutiques les contenant |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA1148165A (fr) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681964A (en) * | 1990-10-23 | 1997-10-28 | University Of Kentucky Research Foundation | Permeable, non-irritating prodrugs of nonsteroidal and steroidal agents |
| US6765019B1 (en) | 1999-05-06 | 2004-07-20 | University Of Kentucky Research Foundation | Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids |
| CN115677507A (zh) * | 2021-07-29 | 2023-02-03 | 天地恒一制药股份有限公司 | 氟比洛芬衍生物及其在药物中的应用 |
-
1981
- 1981-03-04 CA CA000372274A patent/CA1148165A/fr not_active Expired
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681964A (en) * | 1990-10-23 | 1997-10-28 | University Of Kentucky Research Foundation | Permeable, non-irritating prodrugs of nonsteroidal and steroidal agents |
| US6765019B1 (en) | 1999-05-06 | 2004-07-20 | University Of Kentucky Research Foundation | Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids |
| US7214710B2 (en) | 1999-05-06 | 2007-05-08 | University Of Kentucky Research Foundation | Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids |
| CN115677507A (zh) * | 2021-07-29 | 2023-02-03 | 天地恒一制药股份有限公司 | 氟比洛芬衍生物及其在药物中的应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4443475A (en) | Amides of acyl-carnitines, process for preparing same and pharmaceutical compositions containing such amides | |
| US3542870A (en) | 1 - (3,5 - dihalo - 4 - hydroxy - phenyl) - 2 - (2-aryloxy or 2 - arylalkyl - isopropylamino)-propanols | |
| EP0354881B1 (fr) | Composés apparentés à l'acétazolamide, procédé pour leur préparation et compositions pharmaceutiques les contenant | |
| US4542127A (en) | Antidiabetic salicylic acid derivatives | |
| CA1148165A (fr) | Esters de l'acide arylepropionique ayant une activite anti-inflammatoire, procede de preparation, et composes pharmaceutiques les contenant | |
| US3886278A (en) | Ammonium carboxylate sebum inhibition process | |
| EP0066242B1 (fr) | Alpha-toxophéryl ester de l'acide picolinique substitué en position 5, son procédé de préparation et composition pharmaceutique le contenant | |
| EP0632026B1 (fr) | Nouveaux dérivés d'alpha amino acides leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
| KR850000570B1 (ko) | 카르니틴의 알콕시-아실유도체의 에스테르 제조방법 | |
| US4379091A (en) | Esters of arylpropionic acids endowed with an anti-inflammatory activity | |
| CA1148166A (fr) | Esters de l'acide arylepropionique ayant une activite anti-inflammatoire, procede de preparation, et composes pharmaceutiques les contenant | |
| US5196567A (en) | Biphenylylpropionic acid derivative, process for preparing the same and pharmaceutical composition containing the same | |
| HU194877B (en) | Process for producing morpholinoethyl-ester-diniflumate of nifluminic acid and pharmaceutical composition containing them | |
| WO1992016496A1 (fr) | Acides amines n-[[4,5-dihydroxy- et 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracene-yl]carbonyle] utiles dans la therapie des pathologies osteoarticulaires | |
| US4367176A (en) | Esters of arylpropionic acids endowed with an anti-inflammatory activity and related pharmaceutical compositions | |
| RU1836330C (ru) | Способ получени полигидроксибензилоксипропаноламинов | |
| US4275068A (en) | Lipid lowering alkylene glycols and ester derivatives thereof | |
| JPS63270663A (ja) | ピリジルアルキルアミンのアルキルカルボキシアミド類、その製造及び医薬組成物 | |
| EP1242381A2 (fr) | Derives de 2-phenyl-quinoleine et leur utilisation en tant qu'agent contractant des muscles lisses | |
| KR810001974B1 (ko) | 1,4-에탄오-10-하이드록시-5-옥소-5H-[1]벤조피라노[3,4-b]피리딘 에스테르의 제조방법 | |
| US4148898A (en) | N-oxy-ajmaline and the use thereof in treating cardiovascular disorders | |
| EP0101633B1 (fr) | Esters pyridinecarboxyliques de dopamine et de ses dérivés N-alkylés | |
| US4075336A (en) | Thiazines and method | |
| FR2708611A1 (fr) | Sel de codéine de l'acide 2-(3-benzoylphényl)propionique, procédé d'obtention et compositions pharmaceutiques le contenant. | |
| EP0663903B1 (fr) | Derives de dihydro-1,2 oxo-2 amino-3 quinoxalines, leur preparation et leur application en therapeutique |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |